LYN - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
BTK	Bruton tyrosine kinase	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib Fostamatinib Zanubrutinib Abivertinib	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Lethal congenital contractural syndrome (LCCS) Type I diabetes mellitus
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 ABT-869 Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Piebaldism Acute myeloid leukemia (AML)
SNCA	synuclein alpha	Amyloid fiber formation	Resveratrol Copper	Lewy body dementia (LBD); Dementia with Lewy bodies (DLB) Parkinson's disease (PD)
STAT3	signal transducer and activator of transcription 3	Interleukin-6 signaling BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction Signalling to STAT3 Senescence-Associated Secretory Phenotype (SASP) Signaling by Leptin POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Association of TriC/CCT with target proteins during biosynthesis Transcriptional regulation of pluripotent stem cells Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling PTK6 Activates STAT3 PTK6 Activates STAT3 Interleukin-20 family signaling MET activates STAT3 MET activates STAT3 Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-37 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-21 signaling Transcriptional regulation of granulopoiesis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Growth hormone receptor signaling	ENMD-1198	Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) Oral cancer
ACTB	actin beta	Translocation of SLC2A4 (GLUT4) to the plasma membrane Gap junction degradation Formation of annular gap junctions Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation HATs acetylate histones Prefoldin mediated transfer of substrate to CCT/TriC Folding of actin by CCT/TriC EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells Adherens junctions interactions Adherens junctions interactions Recycling pathway of L1 Recycling pathway of L1 VEGFA-VEGFR2 Pathway Interaction between L1 and Ankyrins Interaction between L1 and Ankyrins Cell-extracellular matrix interactions B-WICH complex positively regulates rRNA expression RHO GTPases activate IQGAPs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAP2K and MAPK activation UCH proteinases DNA Damage Recognition in GG-NER Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Quercetin Phenethyl Isothiocyanate	Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
CD19	CD19 molecule	PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Coltuximab ravtansine Blinatumomab Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel	Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
CD79A	CD79a molecule	CD22 mediated BCR regulation Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers		Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CD79B	CD79b molecule	CD22 mediated BCR regulation Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Polatuzumab vedotin	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CDKN1B	cyclin dependent kinase inhibitor 1B	SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence RHO GTPases activate CIT Constitutive Signaling by AKT1 E17K in Cancer TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates Cell Cycle FLT3 Signaling FOXO-mediated transcription of cell cycle genes Estrogen-dependent nuclear events downstream of ESR-membrane signaling Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)		Prostate cancer
CREBBP	CREB binding protein	Regulation of gene expression by Hypoxia-inducible Factor RORA activates gene expression BMAL1:CLOCK,NPAS2 activates circadian gene expression Pre-NOTCH Transcription and Translation Pre-NOTCH Transcription and Translation PPARA activates gene expression PPARA activates gene expression Formation of the beta-catenin:TCF transactivating complex Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells NOTCH1 Intracellular Domain Regulates Transcription NOTCH1 Intracellular Domain Regulates Transcription Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production HATs acetylate histones Attenuation phase Notch-HLH transcription pathway Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation SUMOylation of transcription cofactors Regulation of lipid metabolism by PPARalpha Circadian Clock Activation of anterior HOX genes in hindbrain development during early embryogenesis CD209 (DC-SIGN) signaling TP53 Regulates Transcription of Genes Involved in Cytochrome C Release Activation of the TFAP2 (AP-2) family of transcription factors RUNX1 regulates transcription of genes involved in differentiation of myeloid cells RUNX3 regulates NOTCH signaling RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Estrogen-dependent gene expression TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation FOXO-mediated transcription of cell death genes Regulation of FOXO transcriptional activity by acetylation Regulation of FOXO transcriptional activity by acetylation	9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE	Rubinstein-Taybi syndrome
CSF1R	colony stimulating factor 1 receptor	Other interleukin signaling Transcriptional Regulation by VENTX	Imatinib Sunitinib ABT-869 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Choriocarcinoma
EPOR	erythropoietin receptor	Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS	Darbepoetin alfa Erythropoietin Dibromotyrosine Peginesatide Methoxy polyethylene glycol-epoetin beta	Congenital polycythemia; Familial erythrocytosis (ECYT)
FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FCGR2A	Fc fragment of IgG receptor IIa	FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Neutrophil degranulation FCGR3A-mediated IL10 synthesis	Cetuximab Etanercept Human immunoglobulin G Abciximab Alemtuzumab Daclizumab Bevacizumab Catumaxomab Sarilumab	Systemic lupus erythematosus
FCGR2B	Fc fragment of IgG receptor IIb	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Etanercept Human immunoglobulin G Abciximab Tositumomab Alemtuzumab Antithymocyte immunoglobulin (rabbit) Palivizumab Daclizumab Bevacizumab Sarilumab	Systemic lupus erythematosus
GRIA3	glutamate ionotropic receptor AMPA type subunit 3	Activation of AMPA receptors Trafficking of AMPA receptors Trafficking of GluR2-containing AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Synaptic adhesion-like molecules	Glutamic acid Butabarbital Ethanol Lithium cation Aniracetam Talampanel CX-717 Fluciclovine (18F) Lithium citrate Lithium succinate Lithium carbonate	Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
IL7R	interleukin 7 receptor	Interleukin-7 signaling Interleukin-7 signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis		T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
ITPR1	inositol 1,4,5-trisphosphate receptor type 1	PLC beta mediated events Effects of PIP2 hydrolysis Elevation of cytosolic Ca2+ levels DAG and IP3 signaling Role of phospholipids in phagocytosis FCERI mediated Ca+2 mobilization Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Ca2+ pathway cGMP effects Regulation of insulin secretion VEGFR2 mediated cell proliferation Ion homeostasis Ion homeostasis CLEC7A (Dectin-1) induces NFAT activation FCGR3A-mediated IL10 synthesis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Caffeine 1D-myo-inositol 1,4,5-trisphosphate Glycerin	Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)

Search Results for: LYN